We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

7701:TSEShimadzu Corporation Analysis

Data as of 2026-03-14 - not real-time

¥3,868.00

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Shimadzu is trading close to a key support level, with the short‑term moving average just beneath the current price and the longer‑term averages still above, suggesting a potential floor under the market. Technical momentum appears mixed: the RSI points to modest oversold pressure while the MACD shows a bearish divergence, and the histogram remains negative. Volatility is elevated, and the beta is low, indicating the stock moves less than the broader market. The price‑to‑earnings multiple sits well below the industry average, implying a valuation discount, and the dividend yield is modest but the payout ratio suggests sustainability. On the balance sheet, cash holdings are ample relative to debt, providing a strong liquidity cushion. Operating margins are healthy, and revenue is growing at a steady pace, supporting earnings stability. Analyst sentiment leans toward a buy recommendation, with a median target price notably higher than the current level. The combination of a defensive beta, solid cash position, and an attractive dividend makes the stock appealing for income‑focused investors. However, the recent bearish MACD signal and proximity to support caution against aggressive short‑term positioning. Overall, the fundamentals are sound, but the technicals suggest a watchful stance until price stabilizes.
In summary, Shimadzu presents a case of undervalued fundamentals backed by a sustainable dividend and low financial risk, while technical indicators advise patience. The stock’s defensive profile and growth prospects make it a compelling candidate for medium to long‑term accumulation.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price hovering near support
  • bearish MACD histogram
  • RSI indicating oversold conditions

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • valuation discount to industry peers
  • sustainable dividend payout
  • low beta and strong cash position

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • steady revenue growth trajectory
  • diversified product portfolio across scientific and medical segments
  • robust balance sheet with low leverage

Key Metrics & Analysis

Financial Health

Revenue Growth7.00%
P/E Ratio20.0
Debt/Equity2.24
P/B Ratio2.1
Industry P/E33.7

Technical Analysis

TrendNeutral
RSI35.8
Support¥3,773.00
Resistance¥4,408.00
MA 20¥4,081.40
MA 50¥4,193.70
MA 200¥3,889.35
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Target Price¥5,094.55
Upside/Downside31.71%
GradeUndervalued
TypeValue
Dividend Yield1.73%

Risk Assessment

Beta0.33
Volatility28.99%
Sector RiskLow
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.